[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Leukemia volume 22, pages 1026–1034 (2008)Cite this article

Abstract

We have developed a potent, histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 with >200-fold selectivity over the other HDAC isoforms. PCI-34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines. Unlike broad-spectrum HDAC inhibitors, PCI-34051 does not cause detectable histone or tubulin acetylation. Cells defective in T-cell receptor signaling were still sensitive to PCI-34051-induced apoptosis, whereas a phospholipase C-γ1 (PLCγ1)-defective line was resistant. Jurkat cells showed a dose-dependent decrease in PCI-34051-induced apoptosis upon treatment with a PLC inhibitor U73122, but not with an inactive analog. We found that rapid intracellular calcium mobilization from endoplasmic reticulum (ER) and later cytochrome c release from mitochondria are essential for the apoptotic mechanism. The rapid Ca2+ flux was dependent on PCI-34051 concentration, and was blocked by the PLC inhibitor U73122. Further, apoptosis was blocked by Ca2+ chelators (BAPTA) and enhanced by Ca2+ effectors (thapsigargin), supporting this model. These studies show that HDAC8-selective inhibitors have a unique mechanism of action involving PLCγ1 activation and calcium-induced apoptosis, and could offer benefits including a greater therapeutic index for treating T-cell malignancies.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737–749.

    Article  CAS  Google Scholar 

  2. Glozak MA, Sengupta N, Zhang X, Seto E . Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15–23.

    Article  CAS  Google Scholar 

  3. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J . et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006; 23: 607–618.

    Article  CAS  Google Scholar 

  4. Verdin E, Dequiedt F, Kasler HG . Class II histone deacetylases: versatile regulators. Trends Genet 2003; 19: 286–293.

    Article  CAS  Google Scholar 

  5. Kelly WK, Marks PA . Drug insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150–157.

    Article  CAS  Google Scholar 

  6. Marks PA, Breslow R . Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84–90.

    Article  CAS  Google Scholar 

  7. Xu WS, Parmigiani RB, Marks PA . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541–5552.

    Article  CAS  Google Scholar 

  8. Garber K . HDAC inhibitors overcome first hurdle. Nat Biotechnol 2007; 25: 17–19.

    Article  CAS  Google Scholar 

  9. Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.

    Article  CAS  Google Scholar 

  10. Rosato RR, Grant S . Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 2004; 13: 21–38.

    Article  CAS  Google Scholar 

  11. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL . Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389–4394.

    Article  CAS  Google Scholar 

  12. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567–8572.

    Article  CAS  Google Scholar 

  13. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307: 720–728.

    Article  CAS  Google Scholar 

  14. Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM . Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007; 17: 2874–2878.

    Article  CAS  Google Scholar 

  15. Karagiannis TC, El Osta A . Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007; 21: 61–65.

    Article  CAS  Google Scholar 

  16. Wang DF, Helquist P, Wiech NL, Wiest O . Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 2005; 48: 6936–6947.

    Article  CAS  Google Scholar 

  17. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004; 101: 15064–15069.

    Article  CAS  Google Scholar 

  18. Buggy JJ, Sideris ML, Mak P, Lorimer DD, McIntosh B, Clark JM . Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 2000; 350 (Pt 1): 199–205.

    Article  CAS  Google Scholar 

  19. Gregoretti IV, Lee YM, Goodson HV . Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17–31.

    Article  CAS  Google Scholar 

  20. Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A et al. Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J 2005; 19: 966–968.

    Article  CAS  Google Scholar 

  21. Lee H, Sengupta N, Villagra A, Rezai-Zadeh N, Seto E . Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol 2006; 26: 5259–5269.

    Article  CAS  Google Scholar 

  22. Lee H, Rezai-Zadeh N, Seto E . Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 2004; 24: 765–773.

    Article  CAS  Google Scholar 

  23. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004; 12: 1325–1334.

    Article  CAS  Google Scholar 

  24. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 2006; 5: 1309–1317.

    Article  CAS  Google Scholar 

  25. Tai VW-F, Verner E, Balasubramanian S, Lee CS, Buggy JJ . Indole derivatives as inhibitors of histone deacetylase. USPTO 2007; PCN 07-39 2007109178/WO-A2.

  26. Schultz BE, Misialek S, Wu J, Tang J, Conn MT, Tahilramani R et al. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 2004; 43: 11083–11091.

    Article  CAS  Google Scholar 

  27. Overbeeke R, Steffens-Nakken H, Vermes I, Reutelingsperger C, Haanen C . Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 1998; 3: 115–121.

    Article  CAS  Google Scholar 

  28. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833–10838.

    Article  CAS  Google Scholar 

  29. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM . Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21: 1773–1782.

    Article  CAS  Google Scholar 

  30. Ohashi PS, Mak TW, Van den EP, Yanagi Y, Yoshikai Y, Calman AF et al. Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer. Nature 1985; 316: 606–609.

    Article  CAS  Google Scholar 

  31. Zhang W, Irvin BJ, Trible RP, Abraham RT, Samelson LE . Functional analysis of LAT in TCR-mediated signaling pathways using a LAT-deficient Jurkat cell line. Int Immunol 1999; 11: 943–950.

    Article  CAS  Google Scholar 

  32. Irvin BJ, Williams BL, Nilson AE, Maynor HO, Abraham RT . Pleiotropic contributions of phospholipase C-gamma1 (PLC-gamma1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-gamma1-deficient Jurkat T-cell line. Mol Cell Biol 2000; 20: 9149–9161.

    Article  CAS  Google Scholar 

  33. Patterson RL, van Rossum DB, Nikolaidis N, Gill DL, Snyder SH . Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling. Trends Biochem Sci 2005; 30: 688–697.

    Article  CAS  Google Scholar 

  34. Smith RJ, Sam LM, Justen JM, Bundy GL, Bala GA, Bleasdale JE . Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J Pharmacol Exp Ther 1990; 253: 688–697.

    CAS  Google Scholar 

  35. Tu CL, Chang W, Bikle DD . Phospholipase cgamma1 is required for activation of store-operated channels in human keratinocytes. J Invest Dermatol 2005; 124: 187–197.

    Article  CAS  Google Scholar 

  36. Aires V, Adote S, Hichami A, Moutairou K, Boustani ES, Khan NA . Modulation of intracellular calcium concentrations and T cell activation by prickly pear polyphenols. Mol Cell Biochem 2004; 260: 103–110.

    Article  CAS  Google Scholar 

  37. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH . Cytochrome c binds to inositol (1, 4, 5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol 2003; 5: 1051–1061.

    Article  CAS  Google Scholar 

  38. Yoshida I, Monji A, Tashiro K, Nakamura K, Inoue R, Kanba S . Depletion of intracellular Ca2+ store itself may be a major factor in thapsigargin-induced ER stress and apoptosis in PC12 cells. Neurochem Int 2006; 48: 696–702.

    Article  CAS  Google Scholar 

  39. Navarrete C, Sancho R, Caballero FJ, Pollastro F, Fiebich BL, Sterner O et al. Basiliolides, a class of tetracyclic C19 dilactones from Thapsia garganica, release Ca(2+) from the endoplasmic reticulum and regulate the activity of the transcription factors nuclear factor of activated T cells, nuclear factor-kappaB, and activator protein 1 in T lymphocytes. J Pharmacol Exp Ther 2006; 319: 422–430.

    Article  CAS  Google Scholar 

  40. Treiman M, Caspersen C, Christensen SB . A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. Trends Pharmacol Sci 1998; 19: 131–135.

    Article  CAS  Google Scholar 

  41. Wozniak AL, Wang X, Stieren ES, Scarbrough SG, Elferink CJ, Boehning D . Requirement of biphasic calcium release from the endoplasmic reticulum for Fas-mediated apoptosis. J Cell Biol 2006; 175: 709–714.

    Article  CAS  Google Scholar 

  42. Szabadkai G, Rizzuto R . Participation of endoplasmic reticulum and mitochondrial calcium handling in apoptosis: more than just neighborhood? FEBS Lett 2004; 567: 111–115.

    Article  CAS  Google Scholar 

  43. Wilde JI, Watson SP . Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell Signal 2001; 13: 691–701.

    Article  CAS  Google Scholar 

  44. Wang D, Feng J, Wen R, Marine JC, Sangster MY, Parganas E et al. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity 2000; 13: 25–35.

    Article  Google Scholar 

  45. Liu KQ, Bunnell SC, Gurniak CB, Berg LJ . T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J Exp Med 1998; 187: 1721–1727.

    Article  CAS  Google Scholar 

  46. Lin TA, McIntyre KW, Das J, Liu C, O'Day KD, Penhallow B et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry 2004; 43: 11056–11062.

    Article  CAS  Google Scholar 

  47. Braiman A, Barda-Saad M, Sommers CL, Samelson LE . Recruitment and activation of PLCgamma1 in T cells: a new insight into old domains. EMBO J 2006; 25: 774–784.

    Article  CAS  Google Scholar 

  48. Katan M . Families of phosphoinositide-specific phospholipase C: structure and function. Biochim Biophys Acta 1998; 1436: 5–17.

    Article  CAS  Google Scholar 

  49. Fatkins DG, Zheng W . A spectrophotometric assay for histone deacetylase 8. Anal Biochem 2008; 372: 82–88.

    Article  CAS  Google Scholar 

  50. Smith BC, Denu JM . Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J Biol Chem 2007; 282: 37256–37265.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Biology, Pharmacyclics Inc., Sunnyvale, CA, USA

    S Balasubramanian, J Ramos, M Sirisawad & J J Buggy

  2. Department of Chemistry, Pharmacyclics Inc., Sunnyvale, CA, USA

    W Luo & E Verner

Authors
  1. S Balasubramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Sirisawad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Verner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J J Buggy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Balasubramanian.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balasubramanian, S., Ramos, J., Luo, W. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026–1034 (2008). https://doi.org/10.1038/leu.2008.9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.9

Keywords

This article is cited by

Search

Advanced search

Quick links